Danilo Santana Galvão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danilo Santana Galvão has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Do Rosário Esteves Guimarães
Postgraduate Program in Pharmacy, Faculty of Pharmacy, Federal University of Bahia
1 shared publication - Humberto Fonseca de Freitas
Postgraduate Program in Program in Pharmaceutical Science, School of Pharmacy, State University of Feira de Santana
1 shared publication - Silvio Cunha
Instituto de Química, Universidade Federal da Bahia, Campus de Ondina, Salvador, Bahia 40170-115, Brazil
1 shared publication - Tânia Fraga Barros
Doutora em Farmácia - Universidade Federal da Bahia
1 shared publication
Latest Publications
- 5 February 2025
- Published by Taylor & Francis in Biofouling
- Vol. 41 (2) , 197-210
Thiosemicarbazones and analogues as potential biofilm inhibitors of Candida albicans
Biofilms are a virulence factor for Candida albicans, a common pathogen in human fungal infections, making them resistant to many commercial antifungals. Therefore, the discovery of compounds that inhibit and eradicate biofilms is a priority. As thiosemicarbazones have had their effect on Candida biofilms little explored, this study investigated the inhibitory and eradication activity of 30 thiosemicarbazones and analogues against C. albicans biofilms. After initial screening, four compounds were selected and compound 28 emerged as the most potent with BIC50 at 31.55 ± 1.18 µM. By scanning electron microscopy analysis, blastoconidia adhered to the reduced surface and reduced formation of pseudohyphae and hyphae was revealed. Despite the inhibitory activity, the four compounds failed to eradicate the biofilm by more than 50%. Thus, the results suggest that the compounds evaluated are very promising for the development of effective antibiofilm compounds and open up new perspectives for elucidating the mechanism of action.
- 5 February 2025
- Published by Taylor & Francis in Biofouling
- Vol. 41 (2) , 197-210
Thiosemicarbazones and analogues as potential biofilm inhibitors of Candida albicans
Biofilms are a virulence factor for Candida albicans, a common pathogen in human fungal infections, making them resistant to many commercial antifungals. Therefore, the discovery of compounds that inhibit and eradicate biofilms is a priority. As thiosemicarbazones have had their effect on Candida biofilms little explored, this study investigated the inhibitory and eradication activity of 30 thiosemicarbazones and analogues against C. albicans biofilms. After initial screening, four compounds were selected and compound 28 emerged as the most potent with BIC50 at 31.55 ± 1.18 µM. By scanning electron microscopy analysis, blastoconidia adhered to the reduced surface and reduced formation of pseudohyphae and hyphae was revealed. Despite the inhibitory activity, the four compounds failed to eradicate the biofilm by more than 50%. Thus, the results suggest that the compounds evaluated are very promising for the development of effective antibiofilm compounds and open up new perspectives for elucidating the mechanism of action.